The angiotensin II type 1 receptor blocker losartan in clinical practice: A review

Clinical Therapeutics

Volumn 18, Issue 6, 1996, Pages 1058-1067

  Gavras, Haralambos P ^a   Salerno, Christina M ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; SARALASIN ACETATE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; HEADACHE; HUMAN; HYPERTENSION; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VERTIGO;

EID: 0030497736     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80061-0     Document Type: Article

References (10)

1. 8-angiotensin II for understanding and treatment of high blood pressure. Lancet. 1973;2:1045-1048.
2. Gavras H, Flessas A, Ryan TJ, et al. Angiotensin II inhibition: Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977;238:880-882.
3. Case DB, Wallace JM, Keim HJ, et al. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med. 1976;60:825-836.
4. Smith RD, Chiu AT, Wong PC, et al. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
5. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992;42:1020-1029.
6. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25: 1345-1350.
7. MacKay JH. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996; 156:278-285.
8. Soffer BA, Jackson TW, Pratt JW, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
9. Lacourcière Y, Brunner H, Irwin R, et al, the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 1994;12:1387-1393.
10. ™): A nonpeptide antagonist of angiotensin II. Drugs Today. 1995;31: 463-498.